AbbVie Unusual Options Activity For August 26
AbbVie Unusual Options Activity For August 26
Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie.
投入大量资金的大型投资者对艾伯维公司采取了明显的看好态度。
Looking at options history for AbbVie (NYSE:ABBV) we detected 12 trades.
查看艾伯维公司(NYSE: ABBV)的期权历史记录，我们发现了12次交易。
If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations and 33% with bearish.
如果我们考虑每笔交易的具体情况，可以准确地说有41%的投资者持看涨期望而开仓，33%的投资者持看淡期望而开仓。
From the overall spotted trades, 2 are puts, for a total amount of $315,800 and 10, calls, for a total amount of $347,600.
从总的披露交易中，有2次看跌交易，总金额为315,800美元，10次看涨交易，总金额为347,600美元。
Predicted Price Range
预测价格区间
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $170.0 to $230.0 for AbbVie over the recent three months.
根据交易活动，重要投资者似乎将目标价位设定在170.0美元至230.0美元之间的区间，以涵盖艾伯维公司最近三个月的价格区间。
Volume & Open Interest Trends
成交量和未平仓量趋势
In today's trading context, the average open interest for options of AbbVie stands at 2746.5, with a total volume reaching 2,563.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AbbVie, situated within the strike price corridor from $170.0 to $230.0, throughout the last 30 days.
在当今的交易环境中，艾伯维公司期权的平均未平仓量为2746.5，总交易量达到2,563.00。随附的图表显示了在过去30天内，位于170.0美元至230.0美元的行权价格走廊内的高价值交易的看涨和看跌期权成交量和未平仓量的变化情况。
AbbVie Call and Put Volume: 30-Day Overview
艾伯维看涨和看跌成交量：30天概览
Significant Options Trades Detected:
检测到重大期权交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | PUT | SWEEP | BEARISH | 09/20/24 | $2.84 | $2.39 | $2.75 | $195.00 | $272.9K | 432 | 1.0K |
| ABBV | CALL | TRADE | NEUTRAL | 01/17/25 | $10.25 | $9.7 | $9.95 | $200.00 | $69.6K | 7.1K | 6 |
| ABBV | PUT | TRADE | BULLISH | 01/16/26 | $21.9 | $21.3 | $21.45 | $200.00 | $42.9K | 67 | 20 |
| ABBV | CALL | SWEEP | BULLISH | 01/17/25 | $1.8 | $1.72 | $1.8 | $230.00 | $36.0K | 445 | 202 |
| ABBV | CALL | TRADE | NEUTRAL | 01/17/25 | $10.15 | $9.95 | $10.05 | $200.00 | $35.1K | 7.1K | 548 |
| 标的 | 看跌/看涨 | 交易类型 | 情绪 | 到期日 | 卖盘 | 买盘 | 价格 | 执行价格 | 总交易价格 | 未平仓合约数量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 艾伯维公司 | 看跌 | SWEEP | 看淡 | 09/20/24 | $2.84 | $2.39 | $2.75 | $195.00 | 预计下一次财报将在60天后发布。 | 432 | 1.0K |
| 艾伯维公司 | 看涨 | 交易 | 中立 | 01/17/25 | $10.25 | 9.7 | $9.95 | 。 | 69,600美元 | 7.1K | 6 |
| 艾伯维公司 | 看跌 | 交易 | 看好 | 01/16/26 | $21.9 | $21.3 | $21.45 | 。 | $42.9K | 67 | 20 |
| 艾伯维公司 | 看涨 | SWEEP | 看好 | 01/17/25 | $1.8 | 1.72美元 | $1.8 | $230.00 | $36.0K | 445 | 202 |
| 艾伯维公司 | 看涨 | 交易 | 中立 | 01/17/25 | $10.15 | $9.95 | $10.05 | 。 | $35.1K | 7.1K | 548 |
About AbbVie
关于艾伯维公司
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
AbbVie是一家药品公司，其在免疫学（包括Humira、Skyrizi和Rinvoq）和肿瘤学（包括Imbruvica和Venclexta）方面拥有强大的业务。该公司于2013年初从Abbott分拆而来。2020年收购雅培使其在美容业务（包括Botox）中新增了一些产品和药品。
Current Position of AbbVie
艾伯维公司的当前头寸
- With a volume of 1,597,221, the price of ABBV is down -0.08% at $197.4.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 60 days.
- RSI指标暗示该股票可能要超买了。
Expert Opinions on AbbVie
关于艾伯维公司的专家意见
In the last month, 3 experts released ratings on this stock with an average target price of $209.0.
- Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for AbbVie, targeting a price of $209.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $200.
- An analyst from Morgan Stanley persists with their Overweight rating on AbbVie, maintaining a target price of $218.
- 出于谨慎考虑，Cantor Fitzgerald的一位分析师将评级下调为超配，设定了$200的目标价。
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with Benzinga Pro for real-time alerts.
交易期权涉及更高风险，但同时也提供实现更高利润的潜力。精明的交易者通过持续教育、战略性交易调整、利用各种因子以及保持对市场动态的关注来减轻这些风险。使用Benzinga Pro跟踪AbbVie的最新期权交易以获取实时警报。